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Abstract 
 
The cyclic conotoxin analogue cVc1.1 is a promising lead molecule for the development of new 
treatments for neuropathic and chronic pain. The design of this peptide includes a linker sequence 
that joins the N and C termini together, improving peptide stability while maintaining the structure 
and activity of the original linear Vc1.1. The effect of linker length on the structure, activity and 
stability of cyclised conotoxins has been studied previously but the effect of altering the 
composition of the linker sequence has not been investigated. In this study, we designed three 
analogues of cVc1.1 with linker sequences that varied in charge, hydrophobicity and hydrogen 
bonding capacity and examined the effect on structure, stability, membrane permeability and 
biological activity. The three designed peptides were successfully synthesized using solid phase 
peptide synthesis approaches and had similar structures and stability compared with cVc1.1. 
Despite modifications in charge, hydrophobicity and hydrogen bonding potential, which are all 
factors that can affect membrane permeability, no changes in the ability of the peptides to pass 
through membranes in either PAMPA or Caco-2 cell assay were observed. Surprisingly, 
modification of the linker sequence was deleterious to biological activity. These results suggest the 
linker sequence might be a useful part of the molecule for optimisation of bioactivity and not just 
the physiochemical properties of cVc1.1. 
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Introduction 
Conotoxins are disulfide-rich peptides from the venom of marine snails of the Conus genus that 
range in size from 10–30 amino acids including two or more disulfide bonds.1,2 Despite the small 
size of conotoxins, there is vast potential for diversity, including sequence variation and different 
disulfide bond frameworks3,4. This sequence and structural diversity results in individual conotoxins 
being potent and specific ligands for their particular pharmacological target, which includes 
voltage-gated sodium, calcium and potassium channels, nicotinic acetylcholine receptors 
(nAChRs), the norepinephrine transporter (NET), and G protein-coupled receptors.1,2,5,6 Many of 
these targets are in neurological pathways involved in pain transmission and hence conotoxins are 
valuable as leads for drug development and as research tools for mechanistic studies. However, 
despite the fact that conotoxins are highly potent and selective, there are a number of limitations 
associated with peptides as drugs; they have low membrane permeability so have limited oral 
availability and they are typically rapidly degraded in vivo by plasma and tissue peptidases.  
 
As conotoxins are small peptides, they are ideally suited for chemical synthesis using solid phase 
peptide synthesis approaches, which makes them amenable to incorporation of chemical 
modifications to improve in vivo efficacy. A number of studies have focused on improving 
conotoxin stability with the aim of enhancing the biopharmaceutical properties of conotoxins 
through chemical modification. Strategies used have included the introduction of a cyclic 
backbone7-16, substitution of cysteine with selenocysteine14,17-23, lipidation24-26 and incorporation of 
non-peptidic backbone spacers.27 
Our research focus has been on the backbone cyclization of α-conotoxins as a method of 
stabilisation against proteolytic degradation. The α-conotoxins range in size from approximately 8–
22 residues and contain two disulfide bonds in a CysI-CysIII and CysII-CysIV connectivity. The 
spacing of the cysteine residues defines two loop regions (loops 1 and 2) that vary in composition 
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and length, which are stabilised into a helical structure by the disulfide bonds. Subclasses of α-
conotoxins are defined by the number of residues in each of these loop regions, for example, a 4/7 
α-conotoxin contains four residues in loop 1 and seven in loop 2. The α-conotoxins are potent 
antagonists of nicotinic acetylcholine receptors (nAChR) and recently a subset of α-conotoxins has 
been shown to inhibit high voltage- activated calcium channels via a γ-aminobutyric acid type B 
(GABAB) receptor-dependent mechanism.
28,29 Our initial work focused on the cyclization of the 4/7 
α-conotoxin MII where we demonstrated the feasibility of the approach by producing a cyclic 
variant of MII by introducing a short sequence of glycine and alanine residues to link the N and C 
termini13. An MII analogue cyclized using a 5-residue linker had a distorted structure and reduced 
biological activity, whereas cyclic MII analogues with 6- or 7- residue linkers possessed a structure, 
potency and selectivity consistent with the linear wild-type conotoxin. 
 
Several other studies have investigated the effect of linker length on the activity and stability of 
cyclized α-conotoxins from other subclasses. A study on the cyclization of the 4/3 α-conotoxin ImI 
used short linker sequences of one to three amino acids, which resulted in preferential formation of 
a less active non-native disulfide isomer.15 Two studies on the backbone cyclization of the 4/6 α-
conotoxin AuIB also examined the influence of linker length upon oxidative folding of AuIB.7,14 A 
5-residue linker provided the highest yield of the native ‘globular’ disulfide isomer (CysI-CysIII, 
CysII-CysIV), whereas a 1-, 3- or 4-residue linker resulted predominantly in the alternative “ribbon” 
isomer (CysI-IV, CysII-III). Cyclic AuIB analogues with 4–7 residues and the globular disulfide 
connectivity displayed the native structure based on NMR studies, but the disorder in the linker 
increased with its length. The globular isomer with the 4-residue linker was produced using 
selective protection of the cysteine residues, and resulted in the highest activity at the α3β4 nAChR 
subtype.7 However, Armishaw et al.14 reported that a 2-residue linker was the most potent at the 
α3β4 nAChR subtype although a detailed structural analysis was not done on this peptide.  
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A study on the 4/3 α-conotoxin RgIA investigated the effect of backbone cyclisation using linkers 
ranging in length from 3–7 residues.10 Linker lengths of 5–7 residues resulted in little structural 
perturbation as determined by NMR spectroscopy and these analogues were also the most 
biologically active. Finally, we designed an orally active analgesic cyclic conotoxin based on the 
4/7 α-conotoxin Vc1.1.12 The N- and C-termini of Vc1.1 are 12 Å apart and based on previous 
cyclization studies of conotoxins and other disulfide-rich peptides, we predicted that a linker length 
of 5–6 residues would be effective at spanning the termini and retain activity. Only the 6-residue 
linker retained activity and showed increased stability in simulated gastric fluid, intestinal fluid and 
human serum over the parent acyclic peptide. Importantly, the cyclic analogue with a 6-amino acid 
linker was orally active in a rat model of neuropathic pain and was 120 times more potent than 
gabapentin. 
 
All of the studies on the cyclization of conotoxins have used linker sequences comprising alanine 
and glycine residues as they are considered biologically “inert” and glycine offers additional 
conformational flexibility. To date, little is known about how linker composition might affect the 
structure, stability and biological activity of backbone cyclized conotoxins. A cyclic derivative of 
the χ-conotoxin MrIA, an inhibitor of the noradrenaline transporter, was developed using a RGD 
sequence to link the N and C termini.11  This cyclic peptide both blocked noradrenaline uptake and 
inhibited aggregation of platelet-rich human plasma. Interestingly, the cyclic MrIA RGD peptide 
was also more stable in rat plasma than a cyclic MrIA analogue with an Ala-Gly linker. Most 
recently, we described the cyclization of the P-superfamily conotoxins gm9a and bru9a, which 
contain three disulfide bonds in a cystine knot arrangement and are topologically similar to the 
cyclotide family of cyclic peptides.16,30 Using a GLP linker sequence, based on the structurally 
analogous loop in the cyclotide kalata B1, cyclic analogues of gm9a and bru9a that were 
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structurally almost identical to the linear parent peptides were produced.16 
 
In this study, we further investigate the role of linker composition on the structure, stability, activity 
and pharmaceutical properties of cyclic conotoxins. Using the cyclic analogue of α-conotoxin 
Vc1.1 as a model peptide, we used molecular dynamics simulations to redesign the linker sequence 
with the aim of improving membrane permeability and structural stability. Following chemical 
synthesis and structural characterization of the new cyclic Vc1.1 analogues, we investigated the 
effects of these linker changes on biological activity in vitro and on membrane permeability in both 
PAMPA and CACO-2 assays. 
 
Materials and Methods 
 
Materials  
Peptide resins, amino acids and reagents were purchased from Chem-Impex International Inc. 
(Wood Dale, IL) and Chempep Inc (Wellington, FL). Human male AB serum was purchased from 
Sigma-Aldrich. Caco-2 cells were kindly provided by Prof. Istvan Toth, The University of 
Queensland. All cell culture reagents were purchased from Gibco, Life Technologies and 
Invitrogen. Lucifer yellow solution was purchased from Sigma-Aldrich and culture plates were 
purchased from Corning Incorporated. Parallel artificial membrane permeability assay (PAMPA) 
plates were obtained from BD Biosciences (North Ryde, NSW).  
 
Linker design by molecular dynamics  
The solution NMR structure of linear Vc1.1 (PDB ID: 2H8S) was used as a template, and cVc1.1 
and linker analogues were constructed using YASARA Dynamics 13.4.24.31 CHARMM topologies 
and parameters for N-methyl groups were calculated using the SwissParam web server32 while 
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those for acetonitrile were obtained from CGenFF 2b8.33 Systems were solvated with TIP3P water 
and neutralized by Na+/Cl- counter ions in VMD 1.9.2.34 This procedure generated systems of 
~10,000 atoms. Each system was equilibrated using a stepwise relaxation procedure using NAMD 
2.1035 as previously described.36 Production simulation runs of 15 ns were performed for each 
compound and simulation snapshots were saved every 5 000 steps producing 15 000 frames for 
analysis. The average simulation structure was chosen as the frame that most closely aligned with 
the average simulation coordinates.   
 The polar surface areas (PSA), surface areas (SA) and virtual log n-octanol/water partition 
coefficients (vLogP) were calculated in VEGA ZZ 3.0.537 from the simulation trajectories for 
cVc1.1-L1, cVc1.1-L2, and cVc1.1-L3, while these parameters for atenolol (PubChem CID 2249) 
and quinidine (PubChem CID 441074) were calculated from their respective known structures. 
 
Synthesis and oxidative folding 
All three peptides were synthesised on PAM-Gly resin by solid phase peptide synthesis38 using a 
CS Bio Synthesizer (CS 336X; Menlo Park, CA). S-trityl-β-mercaptopropionic and the first amino 
acid were coupled manually. All peptides were synthesized using Boc chemistry with an in situ 
neutralization/O-benzatriazole-N, N, N’, N’ - tetramethyluronium hexafluorphosphate (HBTU) 
protocol.39 The side chains of CysII and CysIV were protected with acetamidomethyl (Acm) groups 
to facilitate regioselective disulfide bond formation. Peptides were cleaved from resin using 
hydrofluoric acid (HF) with p-cresol as a scavenger (12:1.5 v/v). The reaction was allowed to 
proceed at -5 to 0 °C for 1.5 h. The HF was removed under vacuum and the peptide was 
precipitated in ether, filtered and solubilized in 50% acetonitrile containing 0.05% trifluoroacetic 
acid (TFA), and lyophilized. 
 
The crude peptides were purified by reverse phase-HPLC on a Phenomenex C18 column using a 
gradient of 0–50% B (Buffer A: H2O/0.05% TFA; Buffer B: 90% CH3CN/10% H2O/0.045% TFA) 
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in 50 min, with the eluent monitored at 215/280 nm. ESI-MS confirmed the molecular mass of the 
synthesized peptide, which was lyophilized before a two-step oxidation protocol was employed. 
The reduced peptides were first oxidized in 0.1 M NH4HCO3 buffer (pH 8.2) at a concentration of 
0.3 mg/ml overnight at room temperature and subsequently purified by RP-HPLC using a gradient 
of 0–50% buffer B in 50 min. The second disulfide bridge was formed by treatment of the peptides 
with iodine under acidic conditions. The peptides were dissolved in buffer A (1 mg/ml) followed by 
slow addition of I2 in CH3CN until solution became yellow/dark brown. The reaction mixture was 
then stirred for 15 min at 37°C before it was quenched by addition of ascorbic acid until the mixture 
became colorless. The completely oxidized peptides were purified by RP-HPLC on a 0.5% 
gradient, and analytical RP-HPLC and ESI-MS confirmed the purity and molecular mass of the 
peptides. Peptide concentration was determined by measuring absorbance at 280 nm and using the 
Beer-Lambert law. The molar extinction coefficients were predicted based on the content of 
tryptophan, tyrosine and cystines.40  
 
NMR spectroscopy  
NMR data were acquired on a Bruker Avance 600 MHz NMR spectrometer equipped with a 
cryoprobe. cVc1.1-L1 and L3 were dissolved in 90% H2O/10% D2O (pH 3.1) and cVc1.1-L2 was 
dissolved in 50% CH3CN/40% H2O/10% D2O (pH 2.5) to a final concentration of 1 mg/ml. 2,2-
dimethyl-2-silapentane-5-sulphonate (DSS) was added as a chemical shift reference (0.0 ppm). 
Two-dimensional spectra for all peptides were recorded at 280 K and processed by Topspin 2.1 
(Bruker). Datasets recorded included homonuclear spectra TOCSY (4–8 scans) with a mixing time 
of 80 ms and NOESY (24–54 scans) with a mixing time of 200 ms, and analyzed using CCP NMR 
software.41 Spectra were recorded with a spectral width of 12 ppm, and a resolution of 4k data 
points in the f2 dimension and 512 increments in the f1 dimension. Spectra were assigned using the 
sequential assignment protocol42 and secondary shifts calculated using the random coil values 
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reported by Wishart et al..43 For N-methylated amino acids random coil values for the unmethylated 
residue were used. 
 
Caco-2 permeability  
Caco-2 cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% 
fetal bovine serum, 1% non-essential amino acids and 1% penicillin-streptomycin and maintained at 
37 °C in 5% CO2 and 90% relative humidity. Cells were seeded when ~90% confluent in 12-well 
membrane plates (PET membrane, 1.12 cm2 growth area, 0.4 µM pore size) at ~50 000 cells/well, 
and cultured for 21 days in order to create the monolayer with media changed every two days. 
Passages 37−48 were used for the experiments. The integrity of the Caco-2 cell monolayer was 
tested by measuring the trans epithelial electrical resistance (TEER) values using an EVOM 
Millicell® ERS-2 voltmeter (Millipore Co.). Following 21 days in cell culture, monolayers 
developed TEER values of 250–400 Ω cm2, which is consistent with an intact cell monolayer. The 
permeability of the monolayer was also tested using Lucifer yellow by measuring the absorption of 
Lucifer yellow at the end of assay. If  >1% Lucifer yellow was absorbed, the cell monolayer was 
shown to no longer be intact and hence results could not be interpreted.   
 
On the day of assay, media was aspirated off and cells washed with Hank’s Buffered Saline 
Solution (HBSS) containing 1.25 mM CaCl2 and 0.5mM MgCl2 (pH 7.4). After, cells were left in 
fresh HBSS solution for 30 min under shaking (55 rpm) at 37°C and TEER values were measured. 
Samples were prepared to a concentration of 50 µM in HBSS with 10 µM Lucifer yellow containing 
solutions, and added to the apical side of the monolayer. Plates were returned to a shaking incubator 
(55 rpm), and 100 µl taken from both basolateral and apical sides after 45 and 90 min of incubation 
to be analyzed for peptide content. 200 µl samples were also taken from both basolateral and apical 
sides after 90 min of incubation for Lucifer yellow absorbance readings to confirm monolayer 
integrity. After 90 min the volumes of the compartments were replenished with HBSS solution to 
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starting volumes, and TEER measurements were repetitively recorded to confirm that the 
monolayer was not breached during assay. Atenolol and quinidine were used as negative and 
positive controls, respectively. Samples were analyzed using LC-MS and apparent permeability 
coefficients (Papp) calculated using equation (1): 
        (1) 
where Area is the surface of the cell monolayer (1.12cm2), CD (0) is the initial concentration of the 
compound applied to the donor chamber, t is the time (s), Mr is the mass of compound in the 
receiver compartment, and dMr/dt is the flux of the compound across the monolayer.  
 
Each peptide was tested in triplicate (3 wells) and repeated 3 times. Peptides were kept in 5 mM 
DMSO and stored at −20°C in between assays.  
 
Parallel Artificial Membrane Permeability Assay (PAMPA)  
PAMPA studies were carried out in 96-well filter plates pre-coated with a lipid-oil-lipid tri-layer 
artificial membrane (BD GentestTM). Before use, the PAMPA plate was warmed to room 
temperature for 30 min. Samples were prepared to a concentration of 50 µM in HBSS with 5% 
DMSO. 300 µl was added to the donor compartments (receiver plate) and the acceptor 
compartments were filled with 200 µl HBSS buffer (filter plate). 
 
The filter plate was coupled with the receiver plate and the resulting construct was covered in 
aluminium foil and incubated at room temperature for 5 h. At the end of the incubation, the plates 
were separated and the final concentrations of compounds were determined by LC-MS. Each 
peptide was tested in triplicate and repeated twice. Peptides were kept in 5 mM DMSO and stored 
at −20°C in between assays. The permeability (Pe) was calculated according to the equation in units 
of cm/s: 
dt
dM
CArea
P r
D
app *
)0(*
1
=
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Permeability (cm/s): Pe = {−ln[1-CA(t)/Ceq]}/A*(1/VD+1/VA)*t] 
 
where A is the filter area (0.3 cm2), VD and VA represent the donor well volume (0.3 ml) and the 
acceptor well volume (0.2 ml), respectively, t is the incubation time in s, CA(t) is the compound 
concentration in acceptor well at time t (mM), CD (t) is the compound concentration in donor well 
at time t (mM) and 
Ceq = [CD(t)*VD+CA(t)*VA]/(VD+VA) 
 
Serum stability  
Serum stability assays were carried out on male AB human serum (Sigma-Aldrich). Two different 
protocols were employed, one using solid phase extraction cartridges; serum was thawed at 37°C 
for 20 min before peptide (1 mg/ml in H2O) was added and vortexed (98:2 v/v). 100 µl samples 
were removed at 0, 2, 4, 6, 8, 10, 12 and 24 h and added to 900 µl 100 mM ammonium acetate (pH 
3.0) to deactivate serum enzymes before incubated on ice for 30 min. Peptides were recovered using 
solid phase extraction cartridges (Phenomenex 60 mg Strata-X polymeric RP cartridges (8B-S100-
UBJ)). First, the cartridge was washed with 6 ml methanol, followed by 3 ml 70% CH3CN: 1% 
formic acid and then 3 ml 1% formic acid to equilibrate the column. Samples were then added to 
the cartridge and washed with 3 ml 1% formic acid before it was eluted with 1.5 ml of the 
appropriate CH3CN concentration and 1% formic acid. The eluted fractions were lyophilized and 
redissolved in 100 µl 1% formic acid before recovery was calculated by LC-MS on a Vydac C18 
column using a 2% gradient. Recovery was calculated based on the peak area for the corresponding 
[M+2H]2+ ion. Vc1.1 and cVc1.1 were used as controls.   
 
Primary Culture of dorsal root ganglion (DRG) Neurons and Patch-Clamp Recordings  
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DRG neurons were enzymatically dissociated from ganglia of 4−16-days-old Wistar rats as 
described previously29 and used for experiments within 24–48 h. Cells were transferred into a 
small-volume (~200 µl) recording chamber constantly perfused with a solution containing (in mM): 
150 tetraethylammonium chloride (TEA-Cl), 2 CaCl2, 10 D-glucose, 10 HEPES, pH 7.4 (with 
NaOH). Borosilicate glass electrodes were filled with an internal solution containing (in mM): 140 
CsCl, 1 MgCl2, 5 MgATP, 0.1 Na-GTP, 5 BAPTA-Cs4, 10 HEPES, pH 7.3 (with CsOH) and had 
resistances of 1.5−2.5 MΩ. Patch-clamp recordings were performed with a Multiclamp 700B 
amplifier controlled by Clampex9.2/DigiData1332 acquisition system (Molecular Devices), at room 
temperature (23–25°C). In DRG neurons, calcium channel currents (ICa) were evoked by 
depolarizing voltage steps of 100 ms duration from a holding potential of −80 mV. Currents were 
filtered at 2 kHz and sampled at 5 kHz. Leak and capacitive currents were subtracted using a −P/4 
pulse protocol. Data are mean ± SEM (n, number of experiments).  
 
Results and Discussion 
 
Linker design/molecular dynamics  
The previously described cyclization linker sequence of cVc1.1 contains a series of Gly and Ala 
residues (Figure 1, Table 1). We investigated how modulating the linker sequence of cVc1.1 would 
affect stability, permeability and activity of this cyclic conotoxin. N-methylation of amino acids in 
peptides is a common strategy for increasing their hydrophobicity. Since N-methylation can have 
unforeseen consequences for peptide conformation, cVc1.1 and N-methylated linker variants were 
investigated by molecular dynamics. Ideally, compounds of interest would be simulated with their 
target but there was no available structure of the GABAB receptor and the binding site of cVc1.1 is 
unknown, so the analogues were simulated in solution for comparison to cVc1.1 using the α-carbon 
Root-Mean-Square Deviation (RMSD) and intramolecular hydrogen bond patterns. Compounds 
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with more intramolecular hydrogen bonds have less polar groups on their surface to interact with 
water and thus reduce the polarity of the compound.44  
 
Each of the six residues of the cyclisation linker in cVc1.1 was sequentially modelled as N-
methylated to investigate any effects on the conformation and secondary structure of the peptide 
scaffold. The molecular dynamics simulations suggested that N-methylation was structurally well 
tolerated at any position in the linker since the average structure of the variants deviated from 
cVc1.1 with α-carbon RMSD values in the 0.31-0.8 Å range (Table 1).  
 
Satisfied that the whole linker sequence was amendable to N-methylation, we designed a series of 
14 variants with linkers having diverse biophysical properties based on basic, hydrophobic or acidic 
residues (Table 1). The linkers included Gly residues strategically placed in the sequence to aid 
NMR assignment. To explore the effect on membrane permeability by positively charged, 
hydrophobic or acidic residues, three linkers, one from each of the three groups, was chosen to be 
synthesized based on having the lowest α-carbon RMSD compared to cVc1.1 during molecular 
dynamics: GKGKGK (cVc1.1-L1, Figure 2B, residues highlighted in bold being N-methylated), 
GVGVGV (cVc1.1-L2, Figure 2C) and GEGEGE (cVc1.1-L3, Figure 2D). cVc1.1-L2 and cVc1.1-
L3 had both the lowest α-carbon RMSD and the most number of hydrogen bonds within their 
groups. cVc1.1-L1 had the lowest α-carbon RMSD and the second most intermolecular hydrogen 
bonds, and the choice was made on the rationale that structural similarity to cVc1.1 was the most 
important factor. 
 
Synthesis and oxidative folding  
The cyclic analogues were assembled using solid phase peptide synthesis on a CS Bio Synthesizer 
(336X) with Boc/HBTU chemistry. A previous study showed that random oxidation of cVc1.1 gave 
rise to both the ribbon and the globular isomers12 therefore a selective disulfide bond strategy was 
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used to produce the cVc1.1 analogues. This involved incorporating Acm protecting groups to 
facilitate selective formation of the CysI-CysIII and CysII-CysIV disulfide bonds corresponding to the 
native disulfide isomer. The disulfide bonds were formed in two steps under different conditions; 
the first disulfide bond between CysI-CysIII was formed in ammonium bicarbonate buffer at room 
temperature stirring overnight followed by RP-HPLC purification. The second disulfide bond 
between CysII-CysIV was formed by removal of the Acm protecting groups and subsequent 
oxidation in the presence of iodine under acidic conditions. As expected, only the globular isomer 
was observed after folding using this procedure. The fully oxidized peptides were purified by RP-
HPLC, and analytical RP-HPLC and ESI-MS were used to characterize the oxidized peptides 
(Figure 2). ESI-MS of the fully oxidized peptides revealed [M+2H]2+ to be 1180.4 Da for cVc1.1-
L1 (calculated 1179.8 Da), 1143.8 for cVc1.1-L2 (calculated 1143.2 Da) and 1180.7 Da for cVc1.1-
L3 (calculated 1188.2).  
 
NMR analysis  
The purified peptides were analyzed by NMR spectroscopy to confirm the globular α-conotoxin 
fold. All three analogues gave well-dispersed 1H NMR spectra indicating that they adopt ordered 
structures and were further analyzed by two-dimensional NMR. The assignment of the proton 
chemical shifts was done using standard methods42. Briefly, NH-NHi+1, Hα-NHi+1 and Hβ-NHi+1 
connectivities obtained from the NOESY spectra were used in the sequential assignment of 
individual spin systems determined from the TOCSY spectra. Sequential Hα-NHi+1 connectivities 
were observed for almost the entire peptide chains, except at Pro6 and Pro13 as these residues lack 
amide protons. Both prolines were in the trans configuration for all analogues as indicated by 
intense Hα-Hδ NOEs between the preceding residue and the Pro, which matches the data for cVc1.1 
and Vc1.1. Although cVc1.1-L2 and L3 were chemically pure as evaluated by HPLC and MS, extra 
spin systems were present in their NMR spectra, suggesting the presence of a second conformation 
in solution. However, this conformer was only observed for a few residues on either side of Pro13, 
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which is likely due to proline cis/trans isomerization but this could not be confirmed, as the 
conformer could not be fully assigned due to lack of NOEs. Observation of minor conformations in 
solution for small disulfide-rich peptides is not uncommon, and has been reported for other α-
conotoxins, including AuIB.45 
 
Analysis of the secondary shifts can supply information on the secondary structural elements 
present in peptides46. Secondary shifts are the differences between observed Hα shifts and the 
random coil Hα shifts for the corresponding residues.  For example, a series of negative secondary 
Hα shifts suggest an α-helix, which is characteristic for α-conotoxins. Figure 4A shows the 
secondary αH chemical shifts for the synthesized analogues and cVc1.1 indicating negative 
secondary shifts between Gly1−Cys4 and Pro6−Asp11. Negative secondary Hα shifts between Pro 
6−Asp11 have been reported previously for both Vc1.1 and cVc1.112,47 displaying an α-helix in this 
region of the peptide. The analogues follow the same pattern in shifts as cVc1.1 illustrating the high 
degree of structural similarity between the analogues and cVc1.1, which in turn indicates that the 
analogues might have similar bioactivity as cVc1.1. However, there are some variations in the 
linker region, which is due to different linker residues. It should be noted that the data for cVc1.1-
L2 was acquired in 50% acetonitrile, as the peptide was not soluble in 90%H2O/10%D2O, which 
might explain some of the differences in secondary αH shifts for this analogue compared to the 
parent peptide. To investigate the effect of the solvent on the structure of cVc1.1-L2, this compound 
was modelled in 50% acetonitrile. Consistent with the secondary shifts, the average structure of 
cVc1.1-L2 in 50% acetonitrile deviated more from cVc1.1 (α-Carbon RMSD = 0.69 Å) than the 
same compound in water (α-Carbon RMSD = 0.26 Å) (Figure 4B).  
 
Permeability assays 
Caco-2 studies were undertaken to investigate if the chemical properties of the analogues could 
modify the absorption of the α-conotoxin. The human intestinal Caco-2 cell line represents an 
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established in vitro model of the intestinal barrier to study the absorption and metabolism of 
drugs48. Such permeability assays can be used to mimic both the intestinal environment and the 
blood brain barrier and have been shown to correlate to human intestinal absorption.49-51 Table 2 
shows that cVc1.1-L2 tested at a concentration of 50 µM exhibited low permeability, comparable to 
that seen for atenolol, which was applied as a passive paracellular marker and displayed 
permeability (Papp <1 x 10
6 cm/s) consistent with the literature.52-55 cVc1.1, cVc1.1-L1 and cVc1.1-
L3 were not permeable in this assay at a concentration of 50 µM, whereas quinidine, applied as a 
high permeable marker, had permeability values similar to those reported in the literature.52,56,57 A 
comparison of the calculated biophysical properties of cVc1.1-L2 with cVc1.1, cVc1.1-L1 and 
cVc1.1-L3 showed that cVc1.1-L2 had the smallest polar surface area (PSA) and the highest 
lipophilicity (as indicated by vLogP), consistent with cVc1.1-L2 being more permeable (Table 2).  
 
PAMPA determines the permeability of substances from a donor compartment, through a lipid-
infused artificial membrane into an acceptor compartment. Similar to the Caco-2 assay, it is used as 
a high-throughput screening technique. However, PAMPA is solely intended to measure the 
intrinsic ability of compounds to permeate lipophilic barriers (at pH 7.4) as a guide to the possibility 
of passive absorption through the gut wall. Unlike Caco-2 cells, the assay is not complicated by 
influx or efflux mechanisms, or for substances to be absorbed via the paracellular route. As shown 
in Table 2, cVc1.1-L1 was not permeable in the PAMPA system at a concentration of 50 µM, 
which suggests that it is not passively absorbed through the intestine, whereas cVc1.1, cVc1.1-L2 
and L3 displayed low permeability. These findings are consistent with cVc1.1-L1 having the lowest 
vLogP (Table 2) and a charge of +4 at physiological pH, compared to a charge of +1 for the other 
linker variants.  
 
PAMPA and Caco-2 cell assays are the most frequently used high-throughput systems for screening 
of drug absorption of compounds in the early stages of drug discovery. Although the linker 
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analogues and cVc1.1 were tested in both systems and were not permeable in these in vitro 
permeability assays, this might not translate to in vivo models. For example, cyclosporine A, which 
has an oral bioavailability of 20-40% only has a Papp of 1 x 10
6 in the apical to basal direction of the 
Caco-2 assay58 and 1.1 x 106 in RRCK cells.59 Therefore, animal pharmacokinetic studies of cVc1.1 
and linker analogues are required to fully understand the bioavailability of these peptides. 
 
Peptide stability 
The three linker analogues were tested in human serum to determine the effects of the new linker 
sequences on peptide stability. Figure 5 shows that cVc1.1-L3 is the most stable of the linker 
analogues, and cVc1.1-L2 the least stable. At the 24 h time point, there was 73.5 ± 12.3%, 68.6 ± 
9.4% and 91.6 ± 0.3% of cVc1.1-L1, cVc1.1-L2 and cVc1.1-L3 remaining in human serum, 
respectively (n = 9, from three separate experiments). For all analogues, two peaks corresponding to 
the same mass of the individual linker analogues were observed after 2−4 h incubation at 37°C, 
suggesting some re-shuffling of the disulfide bonds in serum. Linear Vc1.1 and cVc1.1 were used 
as controls. cVc1.1 has been reported to be more stable in human serum than its linear analogue 
Vc1.112, which is consistent with the present study. Additionally, cVc1.1-L3 (91.6 ± 0.3%) was 
slightly more stable in human serum than the parent peptide (86.4 ± 4.2%). Previous studies7,8,10-15 
have shown that backbone cyclization of disulfide-rich peptides is an effective approach for 
improving resistance to proteolysis. Typically the linker sequences used in these studies have been 
constructed from functionally inert residues like Ala or Gly and NMR studies have revealed that 
they are usually unstructured in solution.7,10,12,13 Modification of the linker residues to more 
biologically functional residues, such as the charged amino acids used in cVc1.1-L1 and L3, might 
introduce additional protease cleavage sites into the peptide negating the benefits of backbone 
cyclisation. However, this could be counteracted by reduced flexibility of the linker sequence, 
which is likely to reduce susceptibility to proteolysis. Our results showed that cVc1.1-L1 and L2, 
containing positively charged and hydrophobic residues, were the least stable analogues when 
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compared to cVc1.1 and cVc1.1-L3. As the NMR secondary shift analysis revealed that the αH 
secondary shifts of the linker residues for all analogues approximated random coil values we would 
predict that the differences is stability between the peptides is due to the residue composition of the 
linkers in cVc1.1-L1 and L2 being more susceptible to proteolysis rather than the cVc1.1 and 
cVc1.1-L3 linkers providing greater structural rigidity. Consequently, future studies aiming at 
stabilising peptides by linker cyclization may benefit from exploring more diverse amino acid 
functionalities to better understand the balance between linker functionality and rigidity. 
 
Biological activity  
The three linker analogues were tested for their effect on high voltage-activated (HVA) calcium 
channel currents (ICa) in rat DRG neurons. All peptides were tested at a concentration of 500 nM 
because in rat DRG neurons, the half-maximal inhibitory concentration of cVc1.1 is ~0.3 nM and 
500 nM of Vc1.1 was shown to be maximally effective for N-type ICa inhibition.
12 Figure 6 shows 
that cVc1.1-L1 (500 nM)  inhibited a relatively small amount of ICa, whereas cVc1.1-L2 and L3 did 
not affect ICa. Subsequent application of the selective GABABR agonist baclofen or cVc1.1 as 
positive controls, resulted in a further inhibition of ICa (Figure 6B). Figure 6C shows a bar graph of 
the averaged relative peak ICa amplitudes in the presence of cVc1.1-L1, L2, L3, and baclofen 
compared to control. cVc1.1-L1 (500 nM) inhibited ICa by 6.8 ± 1.3% whereas baclofen (50 µM) 
inhibited ICa by 34.9 ± 4%. Although the substitutions in cVc1.1-L3 that introduced carboxylic acid 
groups made large changes to the polarity and dipole moment of the molecule that may interfere 
with receptor binding, it is difficult to rationalize why the conservative substitutions in cVc1.1-L2 
abolished the activity. However, since cVc1.1-L2 was not water soluble, it is possible that the 
delivery of the compound to DRG neurons in a water-based buffer system might not be optimal, 
and the cVc1.1-L2 concentration under these conditions could not be estimated with confidence. 
 
Conclusions 
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In this study the cyclization linker sequence for α-conotoxin cVc1.1 was modified to improve the 
peptide’s stability and pharmacokinetic properties. All linker analogues were found to be 
structurally similar to cVc1.1 and relatively stable in human serum but all had low membrane 
permeability. Surprisingly, despite their structural similarity to cVc1.1, none of the linker analogues 
appreciably inhibited HVA calcium channel currents in DRG neurons. This finding suggests that 
future studies should focus on the role of the linker region in modulating both the activity of cVc1.1 
as well as its pharmacological properties. 
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Figure Legends 
 
Figure 1. Sequences and structures of cVc1.1 linker analogues. (A) A schematic illustrating the 
structure of cVc1.1 and its linker analogues. The peptide contains a helical region that is cross-
braced by two disulfide bonds in a CysI-CysIII and CysII-CysIV pattern. This disulfide pattern forms 
two loop sequences between CysII and CysIII and CysIII and CysIV as indicated. The N and C termini 
are then joined by a linker sequence. (B) Sequences of Vc1.1 and its analogues. The conserved 
cystines are highlighted in yellow and the disulfide bonds and cyclic backbone indicted by the solid 
black line. The linker sequences for each analogue are shown with N-methylated residues 
underlined and highlighted in green. 
 
Figure 2. Molecular dynamics simulations of cVc1.1 and linker analogues. (A) Ribbon plot of 
50 evenly spaced simulation structure frames overlaid with the average simulation structure (left) 
and overlay of the average simulation structure stick models (right) of cVc1.1 (light blue) with 
Vc1.1 (pink). Disulfide bonds are shown in yellow, nitrogens in blue and oxygens in red. Ribbon 
plot of 50 simulation structure frames overlayed with the average simulation structure (left) and 
overlay of the average simulation structure stick models (right) of cVc1.1 (light blue) with (B) 
cVc1.1-L1 (pink), (C) cVc1.1-L2 (pink) and (D) cVc1.1-L3 (pink). 
 
Figure 3. Purity and characterisation of cVc1.1 linker analogues. Analytical RP-HPLC 
chromatograms (left) of cVc1.1-L1 (top), cVc1.1-L2 (middle) and cVc1.1-L3 (bottom) illustrating 
the high degree of purity and relative hydrophobicity of each peptide. To the right are the 
corresponding mass spectra for each peptide, which are consistent with the expected molecular 
weight of the cyclic and oxidised peptides. 
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Figure 4. Structural studies of cVc1.1 and the linker analogues at 280 K. (A) A comparison of 
the secondary Hα shifts of cVc1.1 (filled circles), cVc1.1-L1 (crosses), cVc1.1-L2 (open squares), 
cVc1.1-L3 (open diamonds). The values for each peptide are very similar for each amino acid 
across the sequence. Some variation is seen for cVc1.1-L2 but this is likely due to the NMR data for 
this peptide being recorded in 50:50 acetonitrile/water. The loop and linker regions are indicated on 
the graph. (B) Molecular dynamics simulation of cVc1.1-L2 in 50% acetonitrile. Overlay of the 
average simulation structure stick models of cVc1.1 simulated in water (light blue) with Vc1.1-L2 
simulated in 50% acetonitrile (pink). The structures excluding the linker overlaid with an α-carbon 
RMSD of 0.69 Å. Disulfide bonds are shown in yellow, nitrogens in blue and oxygens in red. 
 
Figure 5. Stability of cVc1.1 linker analogues in human serum. Linker analogues were tested for 
their stability in human serum over a 24 h time period. cVc1.1-L3 (open diamonds) was shown to 
have similar stability to cVc1.1 (filled circles). cVc1.1-L1 (crosses) and L2 (open squares) had a 
similar stability, which was less stable than cVc1.1-L3 but slightly improved compared to linear 
Vc1.1 (filled triangles). Data points are means ± SEM from 3−4 separate experiments.   
 
Figure 6. Effect of cVc1.1-L1, cVc1.1-L2 and cVc1.1-L3 peptides on whole-cell calcium 
channel currents (ICa) in rat DRG neurons. A, Compounds cVc1.1-L1-3 do not inhibit ICa. Left: 
Time course of ICa peak amplitude in the absence (a) and presence of 500 nM cVc1.1-L1-3 (b, c, d) 
or baclofen (e). ICa were elicited by 200 ms step depolarizations from a holding potential of −80 mV 
to 0mV at a frequency of 0.1 Hz. Right: representative ICa traces at the times indicated by lower 
case letters. Horizontal dotted line indicates zero-current level. Colored bars indicate the duration of 
cVc1.1-L1-3 or baclofen application. B, cVc1.1-L1 (500 nM) has no effect on ICa amplitude, 
whereas cVc1.1 (500 nM) inhibits ICa. Bars indicate cVc1.1-L1 peptide, cVc1.1 or baclofen 
application (left). Experimental procedure and voltage protocol: same as in A. Representative IBa 
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traces (right) are shown at the times indicated by lowercase letters. Horizontal dotted line represents 
zero-current level. C, Averaged relative peak ICa amplitudes (I/Icontrol) ± SEM in the presence of 
cVc1.1-L1-3 (500 nM) or baclofen (50 µM). Peak ICa amplitude was analyzed in the absence and 
presence of cVc1.1-L1, cVc1.1-L2 or cVc1.1-L3, and subsequently baclofen. Maximum ICa 
inhibition with 500 nM cVc1.1-L1 was 6.8 ± 1.3 % (n = 7), whereas cVc1.1-L2 or L3 (500 nM) did 
not inhibit ICa. Baclofen (50 µM) inhibited ICa by 34.9 ± 4 % (n = 7). 
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Table 1. Molecular dynamics simulation 
Linker 
analoguesa,
b 
Intramolecular 
Hydrogen 
Bonds 
α-Carbon 
RMSD 
Values (Å)c 
cVc1.1 
GGAAGG 7.56 ± 0.13 - 
Single residue N-methylation 
GGAAGG 7.99 ± 0.34 0.80 
GGAAGG 7.25 ± 0.20 0.30 
GGAAGG 7.55 ± 0.26 0.73 
GGAAGG 8.39 ± 0.71 0.40 
GGAAGG 7.85 ± 0.12 0.50 
GGAAGG 5.98 ± 0.12 0.31 
Hydrophobic residues 
GGLLGG 7.04 ± 0.39 0.95 
GGLLGG 8.20 ± 0.30 0.82 
GLGLGL 6.96 ± 0.05 0.64 
GLPGLP 6.56 ± 0.62 0.56 
GVGVGV 7.22 ± 0.13 0.26 
Basic residues 
GKGKGK 7.25 ± 0.41 0.69 
GKGKGK 6.95 ± 0.42 0.65 
GKPGKP 6.86 ± 0.55 0.65 
GGKKGG 7.28 ± 0.06 0.62 
GKGKGK 6.43 ± 0.30 0.48 
GKGKGK 8.06 ± 0.08 0.33 
Acidic residues 
GGDDGG 7.47 ± 0.16 0.78 
GDGDGD 6.7 8± 0.10 0.55 
GEGEGE 8.17 ± 0.12 0.24 
a Sequences are GCCSDPRCNYDHPEIC-XXXXXX 
where X represents the linker sequences 
b 
N-methylated residues are highlighted in bold font 
c α-Carbon RMSD excludes the linker 
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 Table 2. Caco-2 and PAMPA permeability and in silico calculated biophysical parameters 
Compound Caco-2 
permeability  
x 10
6 
± SEM 
(cm/s
-1
) 
PAMPA 
permeability  
X 10
6 
± SEM 
(cm/s
-1
) 
PSA ± SD
b
 SA ± SD
b
  vLogP ± SD
b
 
Atenolol  0.275 ± 0.125 0.033 ± 0.011 166
 
570 1.5 
Quinidine 17.330 ± 0.675 6.140 ± 0.580 67 575 2.6 
cVc1.1 nd
a 
0.008 ± 0.004 814 ± 32 1878 ± 50 -9.1 ± 0.5 
cVc1.1-L1 nd
a 
nd
a
 960 ± 57 2236 ± 80 -17.1 ± 0.9 
cVc1.1-L2 0.367 ± 0.200 0.006 ± 0.005 713 ± 33 2040 ± 34 -5.4 ± 0.4 
cVc1.1-L3 nd
a 
0.005 ± 0.004 1004 ± 39 2091± 44 -10.8 ± 0.6 
PSA: polar surface area, SA: surface area, vLogP: virtual log water/octanol partitioning coefficient 
a 
Non-detectable 
b 
Standard deviations do not apply to atenolol and quinidine calculated from a single structure 
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Figure 1. Sequences and structures of cVc1.1 linker analogues. (A) A schematic illustrating the structure of 
cVc1.1 and its linker analogues. The peptide contains a helical region that is cross-braced by two disulfide 
bonds in a CysI-CysIII and CysII-CysIV pattern. This disulfide pattern forms two loop sequences between 
CysII and CysIII and CysIII and CysIV as indicated. The N and C termini are then joined by a linker 
sequence. (B) Sequences of Vc1.1 and its analogues. The conserved cystines are highlighted in yellow and 
the disulfide bonds and cyclic backbone indicted by the solid black line. The linker sequences for each 
analogue are shown with N-methylated residues underlined and highlighted in green.  
191x71mm (300 x 300 DPI)  
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Figure 2. Molecular dynamics simulations of cVc1.1 and linker analogues. (A) Ribbon plot of 50 evenly 
spaced simulation structure frames overlaid with the average simulation structure (left) and overlay of the 
average simulation structure stick models (right) of cVc1.1 (light blue) with Vc1.1 (pink). Disulfide bonds are 
shown in yellow, nitrogens in blue and oxygens in red. Ribbon plot of 50 simulation structure frames 
overlayed with the average simulation structure (left) and overlay of the average simulation structure stick 
models (right) of cVc1.1 (light blue) with (B) cVc1.1-L1 (pink), (C) cVc1.1-L2 (pink) and (D) cVc1.1-L3 
(pink).  
169x107mm (300 x 300 DPI)  
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Figure 3. Purity and characterisation of cVc1.1 linker analogues. Analytical RP-HPLC chromatograms (left) of 
cVc1.1-L1 (top), cVc1.1-L2 (middle) and cVc1.1-L3 (bottom) illustrating the high degree of purity and 
relative hydrophobicity of each peptide. To the right are the corresponding mass spectra for each peptide, 
which are consistent with the expected molecular weight of the cyclic and oxidised peptides.  
122x93mm (300 x 300 DPI)  
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Figure 4. Structural studies of cVc1.1 and the linker analogues at 280 K. (A) A comparison of the secondary 
Hα shifts of cVc1.1 (filled circles), cVc1.1-L1 (crosses), cVc1.1-L2 (open squares), cVc1.1-L3 (open 
diamonds). The values for each peptide are very similar for each amino acid across the sequence. Some 
variation is seen for cVc1.1-L2 but this is likely due to the NMR data for this peptide being recorded in 50:50 
acetonitrile/water. The loop and linker regions are indicated on the graph. (B) Molecular dynamics simulation 
of cVc1.1-L2 in 50% acetonitrile. Overlay of the average simulation structure stick models of cVc1.1 
simulated in water (light blue) with Vc1.1-L2 simulated in 50% acetonitrile (pink). The structures excluding 
the linker overlaid with an α-carbon RMSD of 0.69 Å. Disulfide bonds are shown in yellow, nitrogens in blue 
and oxygens in red.  
91x175mm (300 x 300 DPI)  
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Figure 5. Stability of cVc1.1 linker analogues in human serum. Linker analogues were tested for their 
stability in human serum over a 24 h time period. cVc1.1-L3 (open diamonds) was shown to have similar 
stability to cVc1.1 (filled circles). cVc1.1-L1 (crosses) and L2 (open squares) had a similar stability, which 
was less stable than cVc1.1-L3 but slightly improved compared to linear Vc1.1 (filled triangles). Data points 
are means ± SEM from 3−4 separate experiments.  
63x44mm (300 x 300 DPI)  
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Figure 6. Effect of cVc1.1-L1, cVc1.1-L2 and cVc1.1-L3 peptides on whole-cell calcium channel currents 
(ICa) in rat DRG neurons. (A), Compounds cVc1.1-L1-3 do not inhibit ICa. Left: Time course of ICa peak 
amplitude in the absence (a) and presence of 500 nM cVc1.1-L1-3 (b, c, d) or baclofen (e). ICa were elicited 
by 200 ms step depolarizations from a holding potential of −80 mV to 0mV at a frequency of 0.1 Hz. Right: 
representative ICa traces at the times indicated by lower case letters. Horizontal dotted line indicates zero-
current level. Colored bars indicate the duration of cVc1.1-L1-3 or baclofen application. (B), cVc1.1-L1 (500 
nM) has no effect on ICa amplitude, whereas cVc1.1 (500 nM) inhibits ICa. Bars indicate cVc1.1-L1 peptide, 
cVc1.1 or baclofen application (left). Experimental procedure and voltage protocol: same as in A. 
Representative IBa traces (right) are shown at the times indicated by lowercase letters. Horizontal dotted 
line represents zero-current level. (C), Averaged relative peak ICa amplitudes (I/Icontrol) ± SEM in the 
presence of cVc1.1-L1-3 (500 nM) or baclofen (50 µM). Peak ICa amplitude was analyzed in the absence 
and presence of cVc1.1-L1, cVc1.1-L2 or cVc1.1-L3, and subsequently baclofen. Maximum ICa inhibition 
with 500 nM cVc1.1-L1 was 6.8 ± 1.3 % (n = 7), whereas cVc1.1-L2 or L3 (500 nM) did not inhibit ICa. 
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Baclofen (50 µM) inhibited ICa by 34.9 ± 4 % (n = 7).  
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